TrialScope is part of Informa Pharma Intelligence, a division of Informa Business Intelligence, Inc. (IBI). IBI is a wholly-owned subsidiary of Informa PLC.

This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

Industry Leaders Connect at 2018 Strategic Partner Meeting


November 14, 2018

TrialScope Unites Industry Leaders to Address Key Issues of Clinical Trial Disclosure and Transparency at 2018 Strategic Partner Meeting

Company uses event to recognize sponsors’ achievements
in trial reporting with inaugural Cl
ārus Awards

JERSEY CITY, NJ, Nov. 14, 2018 – TrialScope, the global leader in clinical trial transparency and compliance solutions, today announced highlights from its annual Strategic Partner Meeting in New York City, attracting dozens of participants representing global leaders in the pharmaceutical industry. The event is designed to host meaningful discussions between sponsors and industry organizations to improve clinical trial disclosure and transparency on a global scale.

Keynote speakers were Deborah Collyar, Founder and President of Patient Advocates In Research (PAIR), and Jennifer Van Ekelenburg, Head of Human Subject Research Governance and Disclosure at GlaxoSmithKline (GSK).

A cancer survivor, Collyar spoke to the patient perspective of clinical trials and how the level of engagement and satisfaction can ultimately impact a trial’s success. A focus of the evening was the importance of health literacy or ensuring communication with participants is clear and easy to understand.

Van Ekelenburg addressed how GSK’s focus on data transparency builds trust among healthcare professionals, patients and caregivers. She also provided insights on automation technology — robotic process automation (RPA) and cognitive automation such as AI — and its role in the future of disclosure.

To TrialScope CEO, Jeff Kozloff, the annual event represents something bigger than TrialScope and its partners: “Together, as a community, we can increase patient engagement, promote joint decision making and, ultimately, improve outcomes.”

“With increased focus on disclosure and transparency from regulatory agencies, advocacy groups and the public, sponsors are putting more emphasis on compliance than ever before,” said Francine Lane, TrialScope Vice President for Global Transparency. “Our annual summit will continue to be an event where industry leaders can gather to glean insights on issues impacting compliance, discuss common challenges, and celebrate successes.”

Clārus Awards

The 2018 event marked the inaugural Clārus Awards, designed to recognize TrialScope partners for their commitment to clinical trial disclosure and transparency. “Clārus” is a Latin word meaning “clear,” and these awards reflect clarity in clinical trial reporting. This year’s winners include:

  • 2018 Disclosure & Transparency Vanguard: Anke Ehlert, Clinical Trial Disclosure Coordinator, Boehringer Ingelheim.
  • 2018 Disclosure & Transparency Trailblazer: GlaxoSmithKline, for leading the industry in the scope of its transparency commitments and the volume of disclosure. GSK is ranked No. 1 in trial posting, with 3,650 studies on and 1,250 studies on EU CTR. It also is ranked No. 1 in transparency policy by AllTrials.
  • 2018 Compliance Leader: Novo Nordisk A/S

In response to Novo Nordisk’s award, Merete Jørgensen, Senior Clinical Disclosure Director, said, “At Novo Nordisk, we are dedicated to transparency in the clinical trials we conduct, and we strive to ensure compliance with all requirements. We are extremely proud to receive the TrialScope Clārus Award for Compliance Leader 2018!”

For more information on TrialScope, visit

About TrialScope 

TrialScope is the global leader in clinical trial disclosure and transparency management technology, supporting 13 of the top 15 industry clinical trial sponsors worldwide. TrialScope provides proven solutions designed to optimize the efficiency of disclosure activities, maximize trial data transparency, and foster more informed, engaged patients through open research sharing. To learn more about TrialScope, visit